Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Clinical trial NCT04626518 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04626518
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-17
- Primary completion
- 2026-08-21
- Enrollment
- 370
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.